Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia. In addition, in a subgroup of patients who required high-flow oxygen, investigators found that interferon beta-1a was associated with more adverse events and worse outcomes. These findings were published today in the journal The Lancet Respiratory Medicine.
See H Scott post for link.

~ Equalizer, Y@h00 RLFTF finance conversations

—————————————————-

In case no one else posted this another possible covid cure has gone by the wayside.

https://www.nih.gov/news-events/news-releases/interferon-does-not-improve-outcomes-hospitalized-adults-covid-19

~ H. Scott, Y@h00 RLFTF finance conversations